You are here

Home » Content

TO PREPARE AN ORAL FORM OF GLICLAZIDE SR (SUSTAINDEDE RELEASE) 30 MG TABLET AND MANUFACTURING PROCESS DESCRIBING THE FORMULATION AND PROCESS PARAMETERS.

Journal Name:

  • The International Journal of Pharmaceutical Research and Bio-Science

Publication Year:

  • 2012

Key Words:

Author Name
Abstract (2. Language): 
Gliclazide contains not less than 99.0 per cent and not more than the equivalent of 101.0 per cent of 1 (hexahydrocyclopenta[c]pyrrol-2(1H)-yl)- methylphenyl)sulphonyl]urea, The primary mechanism of action of gliclazide in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells. Gliclazide has been shown have extra pancreatic effects like reduction adhesiveness and aggregation and increase in fibrinolytic activity. Minimize dosing frequency, Minimizes fluctuations in serum drug levels, for a drug having narrow therapeutic index, to achieve zero order release rate of drug, Patients compliance. In preparation of Gliclazide having ingredients CHPD, Mg-Sterate, Colloidal Silica, HPMC and Maltodextrin compatible with each other .In this preparation Gliclazide SR - 30 mg having less cost effective and Intended for single dose administration per day & better with sharping effect against diabetic condition.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon 9-8-0-ijprbs-152.8.pdf
  • 5
149-159
  • English

REFERENCES

References: 

1. Asgar A and Sharma SN: Evaluation of
oral sustained release formulation. The East
Pharm. 1991: 69-74.
2. Haider SS, Monnujan N and Shahriyar
SM: Sustained release preparation of
metoclopramide hydrochloride based on
fatty matrix. Indian Drugs 2002; 39:73-9.
3. Reynolds JEF and Ed. Martindale: The
Extra Pharmacopoeia XXX, 30th ed.;
CONCLUSION REFERENCES
Review Article ISSN: 2277-8713
Nirav Soni, IJPRBS, 2012; Volume 1(5): 149-159 IJPRBS
Available Online At www.ijprbs.com
Pharmaceutical Press: London, 1993; pp
279–280.
4. Dollery SC: Ed. Therapeutic Drugs;
Churchill Livingstone: London, 1991.
5. Harrower AD: Comparison of efficacy,
secondary failure rate and complications of
sulfonylurea. J. Diabetes Complicat. 1994; 8:
201–203.
6. Palmer KJ and Brogden RN: Gliclazide,
an update of its pharmacological properties
and therapeutic efficacy in NIDDM. Drugs
1993; 46: 92–125.
7. Yie WC: Novel Drug Delivery Systems.
2nd Ed. New York: Marcel Dekker Inc; 1992
8. Robinson JR and Lee V: Controlled Drug
Delivery Fundamentals and Applications.
2nd Ed. New York: Marcel Dekker Inc: 373-
374.
9. Banker GS and Rhodes CT: Modern
Pharmaceutics. 3rd Ed. New York: Marcel
DekkerInc. 1996; 575-609.
10. Gudsoorkar VR and Rambhau D:
Sustained release of drugs. The East Pharm.
1993; 36:17-22.
11. Lachman L, Lieberman HA and Kanig JL:
The Theory and Practice of Industrial
Pharmacy. 3rd ed. Mumbai: Varghese
Publishing House. 1987: 293-345.
12. Vyas SP and Khar RK: Controlled Drug
Delivery: Concepts and Advances. 1st ed.
Delhi: Vallabh Prakashan. 2002.
13. Alderman DA: Swellable matrices as
systems for oral delivery. Int J Pharm. 1984;
1-5.
14. Nigayale AG: Investigation of prolonged
drug release from matrix formulation of
chitosan. Drug Dev Ind Pharm. 1990; 16:
449-67.
15. Gomez AD: Role of water-uptake on
tablet disintegration: design of improved
method for penetration measurements,
Acta Helv. 1986; 61: 22-29.
16. S Biswal: Enhancement of Dissolution
Rate of Gliclazide Using Solid Dispersions
with Polyethylene Glycol 6000’ AAPS
PharmSciTech. 2008; 9 (2).

Thank you for copying data from http://www.arastirmax.com